BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

593 related articles for article (PubMed ID: 21346146)

  • 1. Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma.
    Gerecitano J; Portlock C; Hamlin P; Moskowitz CH; Noy A; Straus D; Schulman P; Dumitrescu O; Sarasohn D; Pappanicholaou J; Iasonos A; Zhang Z; Mo Q; Horanlli E; Rojas CN; Zelenetz AD; O'Connor OA
    Clin Cancer Res; 2011 Apr; 17(8):2493-501. PubMed ID: 21346146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas.
    Sinha R; Kaufman JL; Khoury HJ; King N; Shenoy PJ; Lewis C; Bumpers K; Hutchison-Rzepka A; Tighiouart M; Heffner LT; Lechowicz MJ; Lonial S; Flowers CR
    Cancer; 2012 Jul; 118(14):3538-48. PubMed ID: 22535574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma.
    Craig M; Hanna WT; Cabanillas F; Chen CS; Esseltine DL; Neuwirth R; O'Connor OA
    Br J Haematol; 2014 Sep; 166(6):920-8. PubMed ID: 25039282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib (Velcade), rituximab, cyclophosphamide, and dexamethasone combination regimen is active as front-line therapy of low-grade non-Hodgkin lymphoma.
    Nabhan C; Villines D; Dalal N; Tolzien K; Kozolff M; Starr A
    Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):26-31. PubMed ID: 21752745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA).
    Ribrag V; Gisselbrecht C; Haioun C; Salles G; Golfier JB; Ertault M; Ferme C; Briere J; Brice P; Mounier N
    Cancer; 2009 Oct; 115(19):4540-6. PubMed ID: 19593797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
    Flinn IW; van der Jagt R; Kahl BS; Wood P; Hawkins TE; Macdonald D; Hertzberg M; Kwan YL; Simpson D; Craig M; Kolibaba K; Issa S; Clementi R; Hallman DM; Munteanu M; Chen L; Burke JM
    Blood; 2014 May; 123(19):2944-52. PubMed ID: 24591201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma.
    Friedberg JW; Vose JM; Kelly JL; Young F; Bernstein SH; Peterson D; Rich L; Blumel S; Proia NK; Liesveld J; Fisher RI; Armitage JO; Grant S; Leonard JP
    Blood; 2011 Mar; 117(10):2807-12. PubMed ID: 21239695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
    Robak T; Jin J; Pylypenko H; Verhoef G; Siritanaratkul N; Drach J; Raderer M; Mayer J; Pereira J; Tumyan G; Okamoto R; Nakahara S; Hu P; Appiani C; Nemat S; Cavalli F;
    Lancet Oncol; 2018 Nov; 19(11):1449-1458. PubMed ID: 30348538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group.
    Sehn LH; MacDonald D; Rubin S; Cantin G; Rubinger M; Lemieux B; Basi S; Imrie K; Gascoyne RD; Sussman J; Chen BE; Djurfeldt M; Shepherd L; Couban S; Crump M
    J Clin Oncol; 2011 Sep; 29(25):3396-401. PubMed ID: 21810681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.
    de Vos S; Goy A; Dakhil SR; Saleh MN; McLaughlin P; Belt R; Flowers CR; Knapp M; Hart L; Patel-Donnelly D; Glenn M; Gregory SA; Holladay C; Zhang T; Boral AL
    J Clin Oncol; 2009 Oct; 27(30):5023-30. PubMed ID: 19770386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.
    Baiocchi RA; Alinari L; Lustberg ME; Lin TS; Porcu P; Li X; Johnston JS; Byrd JC; Blum KA
    Cancer; 2011 Jun; 117(11):2442-51. PubMed ID: 24048792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma.
    Furman RR; Martin P; Ruan J; Cheung YK; Vose JM; LaCasce AS; Elstrom R; Coleman M; Leonard JP
    Cancer; 2010 Dec; 116(23):5432-9. PubMed ID: 20665890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study.
    Drach J; Huang H; Samoilova O; Belch A; Farber C; Bosly A; Novak J; Zaucha J; Dascalescu A; Bunworasate U; Masliak Z; Vilchevskaya K; Robak T; Pei L; Rooney B; van de Velde H; Cavalli F
    Leuk Lymphoma; 2018 Apr; 59(4):896-903. PubMed ID: 29338540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study.
    Chang JE; Peterson C; Choi S; Eickhoff JC; Kim K; Yang DT; Gilbert LA; Rogers ES; Werndli JE; Huie MS; McFarland TA; Volk M; Blank J; Callander NS; Longo WL; Kahl BS
    Br J Haematol; 2011 Oct; 155(2):190-7. PubMed ID: 21848883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma.
    Cohen JB; Switchenko JM; Koff JL; Sinha R; Kaufman JL; Khoury HJ; Bumpers N; Colbert A; Hutchison-Rzepka A; Nastoupil LJ; Heffner LT; Langston AA; Lechowicz MJ; Lonial S; Flowers CR
    Br J Haematol; 2015 Nov; 171(4):539-46. PubMed ID: 26248505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma.
    Barr PM; Fu P; Lazarus HM; Horvath N; Gerson SL; Koc ON; Bahlis NJ; Snell MR; Dowlati A; Cooper BW
    Br J Haematol; 2009 Oct; 147(1):89-96. PubMed ID: 19656151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.
    Till BG; Li H; Bernstein SH; Fisher RI; Burack WR; Rimsza LM; Floyd JD; DaSilva MA; Moore DF; Pozdnyakova O; Smith SM; LeBlanc M; Friedberg JW
    Br J Haematol; 2016 Jan; 172(2):208-18. PubMed ID: 26492567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia.
    Agathocleous A; Rohatiner A; Rule S; Hunter H; Kerr JP; Neeson SM; Matthews J; Strauss S; Montoto S; Johnson P; Radford J; Lister A
    Br J Haematol; 2010 Nov; 151(4):346-53. PubMed ID: 20880120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial.
    Zinzani PL; Khuageva NK; Wang H; Garicochea B; Walewski J; Van Hoof A; Soubeyran P; Caballero D; Buckstein R; Esseltine DL; Theocharous P; Enny C; Zhu E; Elsayed YA; Coiffier B
    J Hematol Oncol; 2012 Oct; 5():67. PubMed ID: 23088650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.